ArticleRadiation oncology (London, England)2023

Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.

Lu Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.